Hello, Fool! | Login | Signup | My Fool
Dec 4, 2008 7:05 PM ET | Feedback | Site Changes | Help
A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.
View All Commentary (UTHR)
Recs
jennings2 (< 20) Submitted: 5/03/07 3:32 PM : Start Price: $59.21 UTHR Score: 29.97
UTHR owns the US rights to Ovarex, an immune based therapy for ovarian cancer originated from virexx corporation, in ph 3 trials. since I can't put forward REX, due to CAPS rules, UTHR is my placeholder. I think Ovarex has a very good chance of being another Provenge type cancer treatment
Report this Post Replies: 1 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
qasamm (72.25) Submitted: 1/10/08 9:24 AM
Recs: 0 | Rec This
OvaRex missed its clinical endpoint and UTHR closed the program in Dec07.
Report this Post Reply
Terms & Conditions
RSS Headlines
Fool UK